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Abstract Cyclo-oxygenase (COX), also referred to as prostaglandin (PG) endoper-
oxidase synthase, is a key enzymatic mediator in the production of arachidonic
acids to PGs and eicosanoids. Two isoforms of COX exist, namely COX-1 and COX-2,
which have distinct physiological functions and tissue distribution. Epidemiological
studies suggest that regular consumption of aspirin and/or other non-steroidal anti-
inflammatory drugs (NSAIDs), which inhibit COX, could notably reduce the risk of
developing many cancers. COX-2 expression has been shown to increase in many
cancers and cancer cell lines, including human prostate adenocarcinoma. COX-2
may also be upregulated in proliferative inflammatory atrophy (PIA) of the prostate,
a pre-neoplastic lesion. The COX-2 pathway may therefore be a useful target for
chemoprevention of prostate cancer, and there is much interest in exploring this
with the use of COX-2 inhibitor drugs such as celecoxib. While there is concern
regarding the cardiovascular toxicities of coxibs, there is no evidence that there
is any increased risk with the use of celecoxib in the short-term neoadjuvant
setting.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Prostate cancer has now become the most com-
monly diagnosed male malignancy amongst West-
ern nations and its incidence is increasing.1 It is
the second leading cause of cancer-related death
next to lung cancer in men in the USA2 and, despite
the increasing use of PSA, greater than 50% of
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doi:10.1016/j.ijsu.2005.10.002patients still present with, or develop, metastatic
disease.3 Advanced prostate cancer initially re-
sponds to androgen ablation therapy, most proba-
bly due to the restriction of prostatic blood flow
which impairs angiogenic growth; however, pro-
gression to an androgen-independent state with
a further increase in tumour load is inevitable.4 If
prostate cancer is diagnosed and treated at an early
organ-confined stage however, there is a >85%
chance of disease-free survival at 10e15 years.3
Hence it is vital to develop strategies to both pre-
vent prostate cancer and delay its progressionblished by Elsevier Ltd. All rights reserved.
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that selective COX-2 inhibition offers huge promise
in this regard.
The biochemistry of cyclo-oxygenases
Cyclo-oxygenase (COX) is a bi-functional rate
limiting enzyme, containing a COX site, involved
in the production of prostaglandins (PG),5 in the
conversion of arachidonic acid to prostaglandin en-
doperoxide synthases (PGG2), as well as reducing
PGG2 to PGH2 at the peroxidase site6 (see Fig. 1).
The PGs are a varied group of autocrine and
paracrine hormones that mediate many cellular
and physiological functions.6 Many studies have
showed that COX has two distinct isoforms, namely
COX-1 and COX-27; while both enzymes catalyze
the same enzymatic reaction as well as have the
same Km and Vmax values for arachidonic acid, sig-
nificant differences exist with regard to their func-
tions.8 Pairet and Engelhardt8 showed that COX-1
is widely expressed and produced in the great
majority of mammalian cells, is localized on the
human chromosome 9q32eq33.3, spans 25 kb in
size, contains 11 exons, and synthesizes 2.8 kb
mRNA which produces a 68 kDa protein. It per-
forms the cell’s ‘‘house keeping duties,’’ such as
Figure 1 The catalytic actions of COX.the immediate production of prostanoids which
regulate the homeostatic vasculature, water reab-
sorption, gastric acid, renal blood flow and plate-
let aggregation.8 In contrast COX-2 is an 8 kb gene
with 10 exons located on the human chromosome
1q25.2eq25.3, and transcribes a 4.1e4.5 kb mRNA
that encodes a protein of about 68 kDa.8 It is widely
regarded as pro-inflammatory which can be acti-
vated by cytokines, mitogens, growth factors and
tumour promoters at both the transcriptional and
post-transcriptional levels.7 It is involved in the
processes of inflammation, ovulation, and labour
where only a transient PG production is required.7
However, both COX-1 and COX-2 are also found
on the luminal surfaces of the nuclear envelope
and endoplasmic reticulum.9,10
The role of NSAIDs in prostate cancer
It is widely acknowledged that NSAIDs have anal-
gesic, anti-inflammatory, and antipyretic proper-
ties11,12; in recent years there has been huge
interest in whether these drugs also have the abil-
ity to decrease the risk and progression of human
cancers. The importance of these drugs in cancer
chemoprevention has been supported by many ep-
idemiological and experimental studies13 showing
a decreased risk of some cancers, most notably co-
lorectal and breast, in those individuals who regu-
larly consume aspirin or other NSAIDs.13,14 The
abnormal growth of tumour tissue is thought to
cause an inflammatory reaction from the peripher-
al invading cells that is necessary for further
growth, and this can be inhibited by NSAIDs.14,15
Norrish et al.15 reported a tendency towards a re-
duced risk of advanced prostate cancer following
the regular administration of aspirin. Nelson and
Harris16 also correlated the regular daily adminis-
tration of ibuprofen or aspirin with a 66% reduction
in prostate cancer risk. Roberts et al.17 found, in
white men over 60 who regularly consumed
NSAIDs, a lower incidence of prostate cancer com-
pared to the general population over this age.
Pollard and Luckert18 demonstrated in trans-
plantable rat prostate adenocarcinoma III cells,
which were treated with the NSAID piroxicam,
a suppression of tumour growth, metastasis, and
bone degeneration. Furthermore, tumour suppres-
sor effects and a significant decrease in tissue
PGE2 levels have been noted in a chemically in-
duced prostate carcinoma F344 rat model supple-
mented with soluble indomethacin.19 In prostate
cancer-bearing rats treated with indomethacin,
thromboxane synthase inhibitor and nafazatron,
all of which are PG inducers, fewer pulmonary
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controls.19 Gupta et al.20 using the TRAMP mouse
model, demonstrated that celecoxib-fed mice at
16, 24 and 32 weeks of age had significantly lower
prostate cancer volumes and fewer lung and lymph
node metastases compared to controls. Further-
more, celecoxib supplementation led to down-reg-
ulation of COX-2 protein expression and increased
in vivo apoptosis in the dorso-lateral prostates of
these animals.20
However, non-selective NSAIDs such as aspirin,
sulindac and indomethacin can cause platelet
dysfunction, peptic ulceration and kidney damage,
thought to be due to COX-1 inhibitory effects.21e23
Several studies have revealed that the anti-tumor-
igenic action of NSAIDs is mediated by selective
inhibition of COX, especially COX-2.21e23 Hence,
selective COX-2 inhibitors (e.g. melaxicam, cele-
coxib and rofecoxib), the so-called coxibs, should
therefore have less side-effects, as well as exhibit
increased anti-cancer effects, when compared to
conventional NSAIDs.24
COX-2 expression and prostate cancer
Through the work of authors such as Dubois
et al.,25 Leahy et al.,26 and Lipsky27 it has become
widely acknowledged that an enhanced expression
of COX-2 is implicated in the progression of cancer
in most sites in the human body. Prescott and Fitz-
patrick,28 using genetic and clinical studies, pro-
vide unequivocal evidence that the upregulation
of COX-2 is one of the key steps in carcinogenesis;
other studies have demonstrated that the in-
creased expression of COX-2 is sufficient to insti-
gate tumorigenesis in animal models.29 Tiano
et al.30 have shown that skin tumorigenesis is sig-
nificantly reduced in COX-2 knock out mice. Inter-
estingly, the inhibition of COX-2 causes tumour
regression.29 However, there are some inconsisten-
cies to this widely acknowledged observation. For
example, Bol et al.31 have recently demonstrated
that COX-2 overexpression in the skin of transgenic
mice resulted in the regression of cancer
development.
O’Neill and Ford-Hutchinson32 in 1993 reported
that the highest levels of COX-1 and COX-2 were
found in the prostate gland. Recently, Gupta
et al.33 demonstrated that COX-2 is overexpressed
in human prostate adenocarcinoma. They con-
firmed that the mean levels of COX-2 mRNA and
protein expressions were significantly increased
in prostate adenocarcinoma compared with con-
trol samples.33 Yoshimura et al.34 found that
COX-1 was very weakly expressed but that COX-2was highly expressed in prostate cancer cells in
comparison to control samples. In normal prostate
tissues and benign prostatic hyperplasia (BPH)
samples, the expression of both COX isoforms
was found to be very weak,34 whilst the extent
and intensity of immunoreactive COX-2 polypep-
tides were significantly enhanced in prostatic
tumour cells compared to BPH samples. Further
studies using mRNA analysis have confirmed an
increased expression of COX-2 but not COX-1 in
prostate cancer cells.34 These results suggest,
therefore, that prostate cancer cells may generate
COX-2 or that the expression of COX-2 leads to the
development of malignancy.
Kirschenbaum et al.35 analyzed 31 specimens of
prostate carcinoma and 10 specimens of BPH.35
They found that COX-1 was expressed in basal ep-
ithelial cells of BPH tissue, with a 90% positive
staining, and in the smooth muscle cells of pros-
tate cancer cells.35 COX-2 was found to be less ex-
pressed in the basal epithelial cells of BPH tissue,
but was highly expressed in areas of high grade
prostate intraepithelial neoplasia (PIN), and even
more expressed in areas of prostate cancer, with
87% of samples demonstrating immunoreactivity.35
Therefore this study indicates that both COX-1 and
COX-2 are upregulated in human prostate cancer
compared to BPH and that expression of COX-2 is
intermediate between BPH and cancer areas for
PIN tissue.35 Madaan et al.36 also demonstrated
both COX-1 and COX-2 expressions in 82 prostate
cancer specimens as well as 30 BPH specimens,
but with a significant overexpression of COX-2 in
tumour cells in comparison to benign tissue. They
found that COX-1 expression in tumour cells was
equal to that of the benign specimens. The authors
found a significant correlation between increasing
tumour grade and COX-2 expression, suggesting
that COX-2 may play a critical role in the develop-
ment and/or progression of prostate cancer.36 Lee
et al.37 also support the notion of increased COX-2
expression in prostate cancer with 15 out of 18
(83%) prostate cancer samples displaying immuno-
reactivity compared to 22% (4/18) of benign speci-
mens. Uotila et al.38 also demonstrated that the
intensity of COX-2 was stronger in prostate cancer
cells than in the normal surrounding epithelium.
COX-2 was also found to be present in PIN lesions
as well as in the muscular fibres of the BPH speci-
mens.38 Importantly with regards to COX-1 expres-
sion, no significant difference was noted.38 Thus,
Uotila et al.38 concluded that COX-2 was overex-
pressed in both prostate cancer and PIN.
In contrast to the above observations, Zha
et al.39 noted, using immunohistochemical (IHC)
analysis of 144 human prostate cancer cases, no
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prostate cancer or high grade PIN in comparison
to normal prostatic tissue. In this study, positive
staining was only observed on scattered cells in
both the tumour and normal tissue regions, al-
though much more consistently observed in areas
of PIA, known to be pre-neoplastic tissue.39 Other
authors have even suggested that the expression of
COX-2 in human prostate cancer cell lines is rela-
tively down-regulated; in LNCaP, DU145, PC-3
and tumour necrosis factor (TNF) prostate cell
lines, COX-2 expression has been found to be unde-
tectable under baseline conditions, although it has
been shown that it is temporarily induced, under
phorbol ester treatment, in TNF and PC-3 cells.39
Subbarayan et al.40 have interestingly proposed
that basal COX-2 mRNA was found to be higher in
normal prostate epithelial cells when compared
with other prostate carcinoma cell models (PC-3,
LNCaP and DU145). In support of this Hong
et al.41 found COX-2 transcripts to be absent in
LNCaP and PC-3 cells and in another study LNCaP
and PC-3 prostate cancer cells have shown to dis-
play insignificant quantities of COX-1 and COX-2.42
COX-2 dependent and independent
mechanisms of action for coxibs in
prostate cancer
Tjandrawinata and Huges-Fulford43 showed that
increased PG synthesis has both growth-promoting
and positive feedback effects in prostate cancer
(see Fig. 2). They found that prostate carcinoma
cells (PC-3) that were treated with exogenous
Figure 2 The COX-2 dependent and independent
actions of coxibs.PGE2 resulted in increased mitogenesis and COX-
2 upregulation.43 Furthermore, treatment of PC-3
cells with 5 mM flurbiprofen, in the presence of ex-
ogenous PGE2, resulted in enhanced expression of
COX-2 and significant tumour growth.43 Liu et al.44
demonstrated that the increased expression of
COX-2/PGE2 contributed to prostate cancer pro-
gression and development through the initiation
of the IL-6 signalling pathway.
In relation of prostate cancer apoptosis COX-2
overexpression has shown to upregulate Bcl2 ex-
pression in an attempt to decrease tumour apo-
ptosis45; Liu et al.46 have demonstrated, using
human prostate carcinoma LNCaP cells that the
overexpression of COX-2 causes apoptosis inhibi-
tion, and following treatment with a selective
COX-2 inhibitor (NS398) Bcl2 down-regulation en-
sues causing apoptosis induction. Celecoxib, which
inhibits COX-2 selectively, has shown to induce ap-
optosis in both androgen-responsive LNCaP as well
as androgen-unresponsive PC-3 cells through the
inhibition of Akt phosphorylation.47 It has also
been demonstrated that COX-2 expression is initi-
ated by TNFa; this emphasizes the inducibility of
COX-2 in response to a pro-inflammatory stimu-
lus.40 Cumulatively, the above data suggest
a pro-inflammatory, anti-apoptotic, and growth
stimulatory nature of COX-2 in the development
and progression of prostate cancer.
Experimental data suggest that NSAIDs and COX-
2 specific inhibitors (coxibs) exert their chemo-
preventive action via specific inhibition of this
enzyme whilst several studies have proposed the
existence of a COX-2 independent mechanism as
a mode of action of these agents in their ability to
prevent cancer. Sulindac derivatives (examples of
coxibs) block cell growth and promote apoptosis in
PC-3 and LNCaP prostate cancer cells to similar
degrees despite these cell lines expressing COX-2
at varying levels,42 suggesting the involvement of
a COX-2 independent pathway. Another coxib, cel-
ecoxib, has been reported to initiate the process
of apoptosis by interfering with functioning of
Akt,46 which may be one of the underlying mecha-
nisms for the COX-2 independent actions of coxibs
and NSAIDs.
Studies also indicate that induction and pro-
duction of angiogenic factors (neovascularization),
as well as inhibition of E-cadherin production (loss
of cell-to-cell adhesion) and matrix metalloprotei-
nase overexpression (increased invasiveness), are
alternative methods by which COX-2 overexpres-
sion can lead to a potentially malignant pheno-
type.48,49 Liu et al.,50 using PC-3 and LNCaP
prostate cancer cells, demonstrated a correlation
between hypoxia-induced COX-2 expression and
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vascular endothelial growth factor (VEGF). When
treated with the coxib NS398, down-regulation of
VEGF is seen; there is reciprocal upregulation fol-
lowing treatment with PGE2.51 Masferrer et al.51
confirmed VEGF upregulation by COX-2 overex-
pression and down-regulation following coxib ad-
ministration. Liu et al.52 also showed a significant
decrease in VEGF production correlating with pros-
tate cancer regression following the use of a coxib
in PC-3 nude mice. Taken together, these findings
suggest that COX-2 is important in tumour angio-
genesis via a VEGF mechanism, and that coxibs
may cause prostate cancers to regress by inhibiting
this process.41
However, the exact mechanisms by which these
pharmacological agents exert their anti-cancer
effects are controversial and unclear; suffice to
say, there appear to be both COX-2 dependent and
COX-2 independent mechanisms of action, proba-
bly involving Akt interference (pro-apoptotic) and
VEGF down-regulation (anti-angiogenic). The de-
gree to which these mechanisms correlate with
COX-2 expression is controversial, but COX-2 in-
dependent pathways may explain the conflicting
evidence regarding COX-2 mRNA and protein over-
expression in prostate cancer cells.
Adverse effects of coxibs
The major use of coxibs has been in the clinical
management of chronic, painful conditions such as
rheumatoid arthritis, where the prolonged use of
conventional NSAIDs is made difficult due to
resulting gastric and renal adverse effects. Clinical
trials have shown that coxibs are as equally
effective as non-selective NSAIDs for analge-
sia.53,54 The Vioxx gastrointestinal outcomes re-
search (VIGOR) trial55 randomized patients with
rheumatoid arthritis to rofecoxib 50 mg/day or
naproxen 1000 mg/day and found a two-fold re-
duction in gastrointestinal events in the rofecoxib
arm, but also showed a five-fold increase in the in-
cidence of acute myocardial infarction in the rofe-
coxib arm when compared with the naproxen
arm.55 Because there was no placebo arm in the
VIGOR trial these findings could suggest either an
adverse cardiac effect of rofecoxib or a protective
cardiac effect of naproxen.
Graham et al.56 examined a cohort of patients
treated with an NSAID between Jan. 1, 1999, and
Dec. 31, 2001, using data from the Kaiser Perma-
nente (a national integrated managed care organi-
zation providing comprehensive health care to
more than 6 million Californians). Of 2,302,029person-years of follow-up, there were 8143 cases
of serious coronary heart disease, each of which
was risk-set matched with four controls on age,
sex, and health-plan region. The multivariate odds
ratio was 1.59 (95% confidence interval 1.10e2.32)
for all doses of rofecoxib, 1.47 (0.99e2.17) for
25 mg or less daily, and 3.58 (1.27e10.11) for doses
greater than 25 mg daily, all compared with cele-
coxib. Celecoxib was not associated with any in-
creased risk of cardiac events compared with
remote (more than two months ago) NSAID use
(odds ratio 0.84, 0.67e1.04).
The adenomatous polyp prevention on Vioxx
(APPROVe) trial57 examined the effects of rofe-
coxib on the incidence of benign sporadic colonic
adenomas. The manufacturers of rofecoxib,
Merck, were forced to withdraw Vioxx from the
market after the finding that the group assigned
to rofecoxib had a four-fold increased risk of seri-
ous thromboembolic events (mainly acute myocar-
dial infarction and cerebrovascular accident)
compared to the placebo group.58
Hudson et al.59 undertook a retrospective co-
hort study of over 2000 patients prescribed cele-
coxib, rofecoxib, or a non-selective NSAID at
their index admission for congestive cardiac failure
(CCF). The combined risk of death and recurrent
CCF was higher in patients prescribed rofecoxib
or NSAIDs than in those prescribed celecoxib (haz-
ard ratios 1.27 and 1.26, respectively). The cele-
coxib long-term arthritis safety study (CLASS)60
compared celecoxib with either ibuprofen or diclo-
fenac in patients with osteoarthritis or rheumatoid
arthritis, and found no difference in the rates of
myocardial infarction. However, the adenoma pre-
vention with celecoxib (APC) trial61 was suspended
by the US National Cancer Institute (NCI) when it
was found that patients taking 400 mg and
800 mg daily celecoxib had a 2.5-fold and 3.4-
fold increase, respectively, in their risk of experi-
encing a major cardiovascular event compared to
patients on placebo.
Further ongoing trials are awaited, but unfortu-
nately they are mostly being performed in patients
with rheumatoid arthritis (a known risk factor for
cardiac disease) and hence these studies will not
answer the question of the risk:benefit ratio of
short-term use of these drugs in patients at little
or no risk for adverse cardiac events. This is
a crucial issue in determining whether the coxibs
are safe in a chemopreventive role.
In summary, it appears that there are well
justified cardiovascular safety concerns for coxibs
in patients with arthritis and other chronic pain
conditions. Current evidence provides some re-
assurance that celecoxib is safer than other coxibs
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APC trial suggested that celecoxib is still not as
safe as placebo, and further studies are thus
needed to confirm its safety as well as that of
the NSAIDs as a whole.
Current clinical trials of coxibs in
prostate cancer
Clinical trials evaluating the effectiveness of coxibs
in prostate cancer are very limited. A small trial of
R-flurbiprofen in 23 patients with advanced pros-
tate cancer, showed a moderate benefit in 52% of
the patients’ rate of PSA increase.62 This positive
result has led to a large, multicentric trial in men
that have suffered biochemical recurrence following
initial definitive therapy for prostate cancer.63 Par-
ticipants are randomized to 800 mg R-flurbiprofen,
600 mg R-flurbiprofen, or placebo. Primary end-
points are comparative effects on time to clinical
disease progression and changes in PSA velocities.
A small pilot study by Derksen and Pruthi64 exam-
ined the effect of celecoxib 200 mg twice daily
(bd) on PSA kinetics in 13 patients with biochemical
recurrence post-definitive treatment. They found
an inhibitory effect on serum PSA levels in most
patients, with celecoxib significantly increasing
PSA doubling time over the 12-month study dura-
tion. This has prompted the authors to initiate
a larger phase 2 study, this time using celecoxib
400 mg bd in 100 patients with PSA-only recurrence.
As well as PSA kinetics, this study will also assess
time to clinical recurrence.
While the effects of coxibs in advanced prostate
cancer are interesting, we feel that the real poten-
tial benefit of these drugs may be in the neo-
adjuvant setting. This limited exposure will almost
certainly lead to no increase in adverse cardiac
events. The NCI are currently performing a phase
1 trial of a 4-week neoadjuvant course of celecoxib
versus placebo followed by prostatectomy for
high-risk localized prostate cancer patients.65 The
investigatorswill evaluate the effects on angiogenic
factors and PGs in surgical samples. We are
ourselves conducting a similar randomized trial
of 4-week neoadjuvant celecoxib 400 mg bd versus
no drug in patients before radical prostatectomy
for clinically localized disease. Our endpoints
include counts of proliferative, angiogenic, apopto-
tic, and hypoxic factors, plus assessment of COX-2
expression, using immunohistochemical methods
on pre- and post-operative samples. Also,
peri-operative samples are taken for cDNA microar-
ray analysis to investigate if celecoxib alters the
gene expression profiles of these tumours.Conclusions
There is an ever increasing body of epidemiological
evidence for a chemopreventive effect of NSAIDs
and coxibs in many human cancers, including
prostate adenocarcinoma.13e17 This has led to
huge interest in the application of NSAID and cox-
ibs in cancer chemoprevention and treatment.
COX-2 appears to be of more importance in this re-
gard than COX-1, an observation consistent with
the different physiological functions of the two en-
zymes. Indeed, studies have shown increasedCOX-2
expression in prostate cancer in both in vivo and in
vitro models.25e38 Themechanisms of action of cox-
ibs in the cancer setting have proven difficult to elu-
cidate, but both COX-2 dependent and independent
pathways appear to be involved.43e52 Induction of
apoptosis and inhibition of angiogenesis may be
important mechanisms, and studies are currently
under way to investigate this. While there are
well justified concerns with the long-term use of
coxibs in elderly patients with arthritis there is
no evidence that this translates into a risk in the
short-term chemopreventive setting in patients
without cardiac risk factors. This is especially
true of celecoxib, the coxib thought to have the
least damaging risk profile and also the greatest
anti-cancer effects. Further research will deter-
mine whether the risk:benefit ratio for celecoxib
is favourable enough to recommend it in the pre-
vention of prostate cancer.
Key points
 Coxibs have a real anti-cancer effect in both in
vitro and in vivo studies.
 Celecoxib is the most potent coxib with regard
to its anti-cancer properties.
 Celecoxib also appears to have the most fa-
vourable toxicity profile of the coxibs.
 The reasons for celecoxib’s superiority is likely
to be due to its lower selectivity for COX-2 but
greater COX-2 independent mechanisms of
action.
 Future studies focusing on celecoxib may fur-
ther elucidate these mechanisms of action,
but at present the anti-cancer effects are pri-
marily thought to be due to an inhibition of
angiogenesis and a stimulation of apoptosis.
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